OncoMatch/Clinical Trials/NCT04594187
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
Is NCT04594187 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for melanoma.
This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without completion lymph node dissection. Prior studies of patients with more advanced melanoma have shown nodal radiation therapy can decrease the risk of nodal recurrence but it is not known if this same benefit will be seen in patients with high risk sentinel lymph node positive disease who are planned for immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: radiation therapy
Exception: to the nodal area planned for RT such that the prior RT field would be included in the current treatment field
Previous radiation therapy (RT) to the nodal area planned for RT such that the prior RT field would be included in the current treatment field. In other words, treatment on this trial would require re-irradiation of tissues
Cannot have received: complete lymph node dissection
Exception: of the nodal basin containing the positive SLN
Complete lymph node dissection (CLND) of the nodal basin containing the positive SLN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Baptist - MD Anderson Cancer Center · Jacksonville, Florida
- Cooper Hospital UNIV MED CTR. · Camden, New Jersey
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify